Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:GWPH NASDAQ:IONS NASDAQ:SRPT NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$36.81-5.5%$28.68$9.57▼$40.29$5.39B1.132.19 million shs1.88 million shsGWPHGW Pharmaceuticals$218.96$218.59$87.07▼$219.57$6.86B2.15899,771 shsN/AIONSIonis Pharmaceuticals$73.09+0.0%$57.99$23.95▼$74.42$11.65B0.332.21 million shs1.31 million shsSRPTSarepta Therapeutics$22.51-3.6%$19.61$10.41▼$138.81$2.28B0.516.22 million shs4.47 million shsUTHRUnited Therapeutics$433.34+0.2%$385.69$266.98▼$459.48$19.52B0.66841,533 shs506,702 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-5.54%+3.95%+26.36%+119.63%+74.45%GWPHGW Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IONSIonis Pharmaceuticals+0.03%+4.46%+19.49%+75.02%+86.64%SRPTSarepta Therapeutics-3.56%+1.81%+32.02%+59.99%-82.12%UTHRUnited Therapeutics+0.15%-1.51%+7.35%+48.40%+17.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$36.81-5.5%$28.68$9.57▼$40.29$5.39B1.132.19 million shs1.88 million shsGWPHGW Pharmaceuticals$218.96$218.59$87.07▼$219.57$6.86B2.15899,771 shsN/AIONSIonis Pharmaceuticals$73.09+0.0%$57.99$23.95▼$74.42$11.65B0.332.21 million shs1.31 million shsSRPTSarepta Therapeutics$22.51-3.6%$19.61$10.41▼$138.81$2.28B0.516.22 million shs4.47 million shsUTHRUnited Therapeutics$433.34+0.2%$385.69$266.98▼$459.48$19.52B0.66841,533 shs506,702 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-5.54%+3.95%+26.36%+119.63%+74.45%GWPHGW Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IONSIonis Pharmaceuticals+0.03%+4.46%+19.49%+75.02%+86.64%SRPTSarepta Therapeutics-3.56%+1.81%+32.02%+59.99%-82.12%UTHRUnited Therapeutics+0.15%-1.51%+7.35%+48.40%+17.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.78Moderate Buy$43.1417.20% UpsideGWPHGW Pharmaceuticals 0.00N/AN/AN/AIONSIonis Pharmaceuticals 2.80Moderate Buy$78.507.40% UpsideSRPTSarepta Therapeutics 2.03Hold$34.4252.90% UpsideUTHRUnited Therapeutics 2.67Moderate Buy$457.215.51% UpsideCurrent Analyst Ratings BreakdownLatest ARWR, UTHR, IONS, SRPT, and GWPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025IONSIonis PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$86.00 ➝ $90.0010/14/2025SRPTSarepta TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/10/2025UTHRUnited TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$328.00 ➝ $435.0010/8/2025IONSIonis PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$84.00 ➝ $90.0010/8/2025ARWRArrowhead PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.0010/8/2025IONSIonis PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$70.00 ➝ $78.0010/8/2025IONSIonis PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$95.0010/8/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$49.00 ➝ $80.0010/8/2025SRPTSarepta TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$14.00 ➝ $16.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$572.98M8.88N/AN/A$1.54 per share23.90GWPHGW Pharmaceuticals$311.33M22.05$0.01 per share18,588.22$23.48 per share9.33IONSIonis Pharmaceuticals$705M16.52N/AN/A$3.73 per share19.60SRPTSarepta Therapeutics$2.48B0.89$2.35 per share9.58$15.99 per share1.41UTHRUnited Therapeutics$2.88B6.79$28.43 per share15.24$144.34 per share3.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)GWPHGW Pharmaceuticals-$9.02M-$0.24N/A608.22N/A-11.05%-7.46%-6.13%N/AIONSIonis Pharmaceuticals-$453.90M-$1.84N/AN/AN/A-28.25%-45.29%-8.99%10/29/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A2.06N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.6216.9115.764.7240.36%18.73%16.49%10/29/2025 (Estimated)Latest ARWR, UTHR, IONS, SRPT, and GWPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025SRPTSarepta Therapeutics$0.02N/AN/AN/A$331.51 millionN/A10/29/2025Q3 2025IONSIonis Pharmaceuticals-$1.15N/AN/AN/A$131.75 millionN/A10/29/2025Q3 2025UTHRUnited Therapeutics$6.75N/AN/AN/A$812.87 millionN/A8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 million7/30/2025Q2 2025IONSIonis Pharmaceuticals$0.19$0.70+$0.51$0.70$270.90 million$452.00 million7/30/2025Q2 2025UTHRUnited Therapeutics$6.80$6.41-$0.39$6.41$802.13 million$798.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AGWPHGW PharmaceuticalsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.394.874.87GWPHGW Pharmaceuticals0.015.134.31IONSIonis Pharmaceuticals0.992.872.86SRPTSarepta Therapeutics0.842.891.81UTHRUnited TherapeuticsN/A7.266.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%GWPHGW Pharmaceuticals81.00%IONSIonis Pharmaceuticals93.86%SRPTSarepta Therapeutics86.68%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%GWPHGW Pharmaceuticals3.10%IONSIonis Pharmaceuticals2.60%SRPTSarepta Therapeutics7.60%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableGWPHGW Pharmaceuticals1,16131.35 millionN/AOptionableIONSIonis Pharmaceuticals1,069159.39 million155.25 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableARWR, UTHR, IONS, SRPT, and GWPH HeadlinesRecent News About These CompaniesGenerali Asset Management SPA SGR Has $1.79 Million Stock Holdings in United Therapeutics Corporation $UTHR2 hours ago | marketbeat.comMartine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) StockOctober 17 at 7:18 PM | marketbeat.comTD Asset Management Inc Sells 15,633 Shares of United Therapeutics Corporation $UTHROctober 17 at 4:36 AM | marketbeat.comAllspring Global Investments Holdings LLC Raises Stake in United Therapeutics Corporation $UTHROctober 17 at 3:52 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 SharesOctober 16 at 7:16 PM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of StockOctober 16 at 7:16 PM | marketbeat.comJefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent CaseOctober 16 at 4:10 PM | insidermonkey.comAware Super Pty Ltd as trustee of Aware Super Grows Stock Position in United Therapeutics Corporation $UTHROctober 16 at 6:58 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $1,761,720.00 in StockOctober 16 at 5:09 AM | insidertrades.comUnited Therapeutics Corporation $UTHR Shares Acquired by Vanguard Personalized Indexing Management LLCOctober 16 at 3:54 AM | marketbeat.comUnited Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025October 15 at 7:41 AM | finance.yahoo.comUnited Therapeutics to Feature Clinical Data at the CHEST 2025 Annual MeetingOctober 13, 2025 | finance.yahoo.comCallan Family Office LLC Increases Stock Position in United Therapeutics Corporation $UTHROctober 13, 2025 | marketbeat.comInspire Investing LLC Trims Stock Position in United Therapeutics Corporation $UTHROctober 12, 2025 | marketbeat.comPrime Capital Investment Advisors LLC Reduces Stake in United Therapeutics Corporation $UTHROctober 12, 2025 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of StockOctober 11, 2025 | marketbeat.comRBC Capital Sticks to Its Buy Rating for United Therapeutics (UTHR)October 11, 2025 | theglobeandmail.comUnited Therapeutics Corporation $UTHR Shares Bought by Galvin Gaustad & Stein LLCOctober 11, 2025 | marketbeat.comMorgan Stanley Maintains United Therapeutics (UTHR) Equal-Weight RecommendationOctober 11, 2025 | msn.comUnited Therapeutics price target raised to $435 from $328 at Morgan StanleyOctober 10, 2025 | msn.comUnited Therapeutics (NASDAQ:UTHR) Earns Hold (C+) Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025After the Fed's Rate Cut, PNC Could See a Mortgage Refinance BoomBy Jordan Chussler | September 21, 2025Why Wall Street Is Betting Billions on Oklo's Nuclear VisionBy Jeffrey Neal Johnson | September 26, 20253 Defense Stocks Surging as Ukraine Tensions DeepenBy Dan Schmidt | October 5, 2025Memes Are Back: Retail Investors Are Piling Into 3 Quantum StocksBy Dan Schmidt | September 29, 2025ARWR, UTHR, IONS, SRPT, and GWPH Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$36.81 -2.16 (-5.54%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$37.27 +0.46 (+1.25%) As of 10/17/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.GW Pharmaceuticals NASDAQ:GWPHGW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.Ionis Pharmaceuticals NASDAQ:IONS$73.09 +0.02 (+0.03%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$73.06 -0.03 (-0.05%) As of 10/17/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Sarepta Therapeutics NASDAQ:SRPT$22.51 -0.83 (-3.56%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$22.38 -0.13 (-0.58%) As of 10/17/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.United Therapeutics NASDAQ:UTHR$433.34 +0.65 (+0.15%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$434.67 +1.33 (+0.31%) As of 10/17/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
